Cantargia AB’s focus is on the development of a discovery made by Professor Thoas Fioretos and Dr Marcus Järås from Lund University. Their research showed that leukaemia stem cells express a protein on the surface called IL1RAP, which is not expressed to a large extent on normal cells. In collaboration with the founders, Cantargia has developed specific antibodies against IL1RAP. Cantargia’s objective is to develop a new drug that can become an important part of future cancer treatment.
- Bli medlem
- Om SwedenBIO